Bayer Stake In OTC Pravachol Could Influence Bristol OTC Unit Divestiture
This article was originally published in The Tan Sheet
Executive Summary
Bayer could have a financial interest in Bristol-Myers Squibb's consumer franchise due to its Pravachol OTC marketing agreement regardless of whether it purchases the unit
You may also be interested in...
Teva Pravachol Exclusivity Loss Raises Bristol’s Stakes For Switch
Bristol-Myers Squibb has more to gain from an Rx-to-OTC switch of the cholesterol-lowering drug Pravachol (pravastatin) if an FDA decision allowing multiple generics on the market in April 2006 is upheld
Teva Pravachol Exclusivity Loss Raises Bristol’s Stakes For Switch
Bristol-Myers Squibb has more to gain from an Rx-to-OTC switch of the cholesterol-lowering drug Pravachol (pravastatin) if an FDA decision allowing multiple generics on the market in April 2006 is upheld
Teva Pravachol Exclusivity Loss Raises Bristol’s Stakes For Switch
Bristol-Myers Squibb has more to gain from an Rx-to-OTC switch of the cholesterol-lowering drug Pravachol (pravastatin) if an FDA decision allowing multiple generics on the market in April 2006 is upheld